Efficacy and Safety of Inclisiran as Monotherapy in Chinese Adults With Low or Moderate ASCVD Risk and Elevated Low-density Lipoprotein Cholesterol.

Condition:   Primary Hypercholesterolemia or Mixed Dyslipidemia Interventions:   Drug: Inclisiran;   Drug: Matching Placebo for Inclisiran Sponsor:   Novartis Pharmaceuticals Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials